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Abstract: The aim of this study was to investigate the behavior of dental-derived human mesenchymal
stem cells (d-hMSCs) in response to differently surface-treated implants and to evaluate the effect of
d-hMSCs on local osteogenesis around an implant in vivo. d-hMSCs derived from alveolar bone were
established and cultured on machined, sandblasted and acid-etched (SLA)-treated titanium discs with
and without osteogenic induction medium. Their morphological and osteogenic potential was assessed
by scanning electron microscopy (SEM) and real-time polymerase chain reaction (RT-PCR) via mixing of
5 × 106 of d-hMSCs with 1 mL of Metrigel and 20 µL of gel-cell mixture, which was dispensed into the
defect followed by the placement of customized mini-implants (machined, SLA-treated implants) in
New Zealand white rabbits. Following healing periods of 2 weeks and 12 weeks, the obtained samples
in each group were analyzed radiographically, histomorphometrically and immunohistochemically.
The quantitative change in osteogenic differentiation of d-hMSCs was identified according to the type
of surface treatment. Radiographic analysis revealed that an increase in new bone formation was
statistically significant in the d-hMSCs group. Histomorphometric analysis was in accordance with
radiographic analysis, showing the significantly increased new bone formation in the d-hMSCs group
regardless of time of sacrifice. Human nuclei A was identified near the area where d-hMSCs were
implanted but the level of expression was found to be decreased as time passed. Within the limitations
of the present study, in this animal model, the transplantation of d-hMSCs enhanced the new bone
formation around an implant and the survival and function of the stem cells was experimentally proven
up to 12 weeks post-sacrifice.
Keywords: dental-derived human mesenchymal stem cells; titanium disc; rough surface; osteogenesis;
animal study
1. Introduction
The establishment of osseointegration is one of the key factors for the long-term
success of oral implants and many previous studies have reported that osseointegration
can be manipulated and improved by changing implant surface properties [1–8]. It is
generally accepted that a rough surface promotes osseointegration more effectively than
a machined surface by providing an increased surface area for cell attachment, resulting
from an increase in the production of prostaglandin E2 and TGF-b1, which are known to
promote osteoblast differentiation, leading to enhanced subsequent bone formation. [2,3]
Materials 2021, 14, 381. https://doi.org/10.3390/ma14020381 https://www.mdpi.com/journal/materials
Materials 2021, 14, 381 2 of 19
Consequently, mechanical and chemical surface treatments including sand blasting and
acid etching (SLA), anodization, [4] hydroxyapatite coating, [5] plasma treatment, [6] and
UV photofunctionization [7,8] have been used successfully to modify titanium implant
surfaces. Recently, along with the advancement of tissue engineering techniques, many
researchers have attempted to better understand the biological reaction underlying cell
attachment to implant surfaces. Since human mesenchymal stem cells (hMSCs) have
shown potential in the treatment of many diseases including inflammatory disease [9],
diabetes [10], myocardial infarction [11] and liver cirrhosis [12], hMSCs have also been
identified as a key cell type required for osseointegration and bone remodeling [13,14].
Although several investigators have evaluated the effect of implant surface treatment
on osteogenic differentiation of hMSCs in vitro [15–18], there has been less extensive
in vivo literature on the fate of hMSCs on differently surface treated implants for clinical
application. Moreover, although it has been widely recognized that hMSCs obtained from
dental origin have higher proliferation and osteogenic differentiation capacity compared
with those in hMSCs obtained from the iliac crest, functional differences depending on
origin of the cell source have been overlooked in many previous studies. Indeed, it can
be anticipated that greater knowledge regarding the fate of hMSCs on implant surfaces,
especially hMSCs obtained from dental origin, could lead to greater clinical implant success
and further understanding of the underlying mechanisms governing the fate of d-hMSCs.
Therefore, the aim of this study was to investigate the behavior of d-hMSCs in response
to differently surface-treated implants and to evaluate the effect of d-hMSCs on local
osteogenesis around an implant in vivo.
2. Materials and Methods
2.1. Titanium Surface Preparation
In brief, titanium discs with dimensions of 10 mm diameter and 2 mm thickness were
fabricated using commercially pure grade IV titanium alloy (Dentium Co., Ltd., Seoul,
Korea) and either machined or sandblasted with large grits and acid etched (SLA)-treated,
ready to be used for the cell seeding. SLA-treated titanium discs were sandblasted with
aluminum oxide powder (Al2O3)(Dentium Co., Ltd.) and acid-etched with a concentrated
hydrochloric acid (HCL) 37% (Sigma-Aldrich, St. Lous, MO, USA). Prior to usage, all
titanium discs were thoroughly cleaned with distilled water, sterilized and dried with
ethylene oxide (EO) gas (Duksan, Seoul, Korea).
2.2. Cell Preparation
The experiment was approved by the Institutional Research Ethics Committee of the
Yonsei University College of Dentistry (IRB NO.14-0097). Human alveolar bone marrow
from mandibles was obtained from healthy subjects (aged 19–40 years old) who visited the
Yonsei University Dental Hospital. To obtain d-MSCs, bone marrow from alveolar aspirates
(0.5–1.0 mL) was obtained from osteotomy sites during implant surgery using an 18-gauge
needle syringe without contamination of periodontal tissues. Stromal cells including
erythrocytes were plated in a 100-mm tissue culture dish (BD, Pharmingen, CA, USA) and
cultured in 15 mL of DMEM containing 10% FBS (Gibco, Invitrogen Corporation, Grand
Island, NY, USA) and 100 units/mL penicillin G and 100 µg/mL streptomycin. During three
days of cell seeding, unattached cells were withdrawn and attached cells were provided
with a fresh medium. Subsequent passages were performed when cells were approximately
in 80% confluence. Each cell at passages P3-P4 was used for the characterization and
further evaluation. The characterization process involved immunocytochemical analysis,
cell-surface-marker characterization, and induction of osteogenic differentiation to test if
d-hMSCs possessed the basic characteristics of mesenchymal stem cells (data not shown).
2.3. Surface Analysis by SEM
The titanium surfaces were analyzed using a scanning electron microscope (SEM,
Hitachi, S-800, Tokyo, Japan) at 15 Kv accelerating voltage. The samples were then pho-
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tographed at 1, 5 and 7 days after initial culturing for 2 days in standard MSC culture media,
followed by culturing in osteogenic-conditioned media containing 10 mM β-GP, 10 µM
dexamethasone and 50 µM ascorbic acid. To obtain SEM images, the samples were then
fixed in 2% glutaraldehyde-paraformaldehyde buffer, rinsed, dehydrated in graded alcohol
and dried. Their time and surface-dependent morphological changes were analyzed using
a fully computerized high-resolution SEM at three different magnification levels (1:12,
1:1000 and 1:3000).
2.4. Quantitative RT-PCR
Total RNA was isolated using an RNA RNeasy kit (Qiagen, Valencia, CA, USA).
Spectrophotometry and denaturing agarose gel electrophoresis were used to determine the
consistency of the quality of RNA. From 1 µg of purified total RNA, cDNA was synthesized
using a PrimeScript RT reagent kit (Invitrogen), following the directions of the producer.
The primer sequences used have been described in Table 1. With SYBR green real-time
PCR master mix (Thermo Fisher scientific, Waltham, MA, USA), quantitative RT-PCR
analysis was conducted with a 7500 Real-Time PCR System (Thermo Fisher scientific).
The conditions for PCR were 95 ◦C for 30 s, 40 denaturation cycles for 5 s at 95 ◦C and
annealing and extension for 15 s at 60 ◦C, accompanied by dissociation and a typical
denature action curve.
Table 1. RT-PCR primer information.
Gene Name Gene ID Sequences Am Pliconlength (bp)
























Hum an RUNX2 R tgettgaattteccaagg
2.5. Preparation of Customized Implant and Animal Preparation and In Vivo d-hMSC Transplant
Non-threaded type customized implant (Dentium Co., Ltd., Seoul, Korea) with a
diameter of 1.5 mm and height of 3.7 mm were designed and surface-treated (machined or
SLA treated).
In this study, 20 New Zealand white rabbits, 6 weeks old and weighing 3.5–4.0 kg each
were used. A total of 80 samples were randomly distributed to 20 New Zealand white rabbit
as 4 samples can be obtained from a single rabbit (Table 2). The Institutional Animal Care
and Use Committee, Yonsei Medical Center, Seoul, Korea, reviewed and approved animal
collection, management, surgical protocols and procedures for this research (Approval no.
2013-0347-2). The animals were anesthetized with a combination of 30 mg/kg of Zolazepam
(Zoletil Virback Korea Co., Seoul, Korea) and 10 mg/kg of Xylazine HCI (Rumpun, Bayer
Korea, Seoul, Korea) given intravenously, followed by shaving and sterilizing the surgical
site with povidone-iodine. After 10 minutes, infiltration with 2% lidocaine HCl and
epinephrine 1: 80,000 was given. A defect size of 1.0 mm in diameter and 4mm in height
was made using a dental diamond bur and customized implants were placed in the right
and left tibia of the rabbit. According to the study design, 5 × 106 d-hMSCs mixed with
1ml of MetrigelTM (BD) and 20 µL of gel-cell mixture were dispensed into the defect prior
to implant placement. After 2 and 12 weeks post-implantation, animals were sacrificed
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using 2% paraformaldehyde injection to the heart under a general anesthetic condition
(Figure 1). Then, for 2 weeks, block sections including implants were retained and fixed
in 10% neutral buffered formalin. The samples obtained were examined radiographically,
histomorphometrically and immunohistochemically, respectively.
Table 2. The experimental design and classification of animal groups.










d-MSC SLA 10 10
Materials 2021, 14, x FOR PEER REVIEW 4 of 20 
 
placed in the right and left tibia of the rabbit. According to the study design, 5 × 106 d-
hMSCs mixed with 1ml of MetrigelTM (BD) and 20 μL of gel-cell mixture were dispensed 
into the defect prior to implant placement. After 2 and 12 weeks post-implantation, ani-
mals were sacrificed using 2% paraformaldehyde injection to the heart under a general 
anesthetic condition (Figure 1). Then, for 2 weeks, block sections including implants were 
retained and fixed in 10% neutral buffered formalin. The samples obtained were examined 
radiographically, histomorphometrically and immunohistochemically, respectively. 
Table 2. The experimental design and classification of animal groups. 
No. of Samples No. of Animals 2 week Group 12 Week Group 




Control SLA 10 10 




d-MSC SLA 10 10 
 
Figure 1. Surgical procedure used in this study. 
2.6. Radiological Analysis 
New bone volume was determined at two points from plain X-ray images: (a) new 
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ment was performed by one experienced examiner using specific image software (Image-
Pro Plus, Media Cybernetics, Silver Spring, MA, USA). 3D photographs of the samples 
were reconstructed and the amount of fresh bone forming around implants was deter-
mined using micro-computed tomography scanners (SkyScan 1076, Skyscan, Aartselarr, 
Belgium) inside the area of interest (ROI) box at a resolution of 35 um (achieved using 100 
kV and 100 uA). ROI box was set with dimension of 1.30 mm (x axis) × 1.30 mm (y axis) × 
0.45 mm (z axis) (Figure 3). 
Figure 1. Surgical procedure used in this study.
2.6. Radiological Analysis
New bone volume was determined at two points from plain X-ray images: (a) new
bone volume (µm × µm) formed from the implant head, (upper) and (b) new bone volume
(µm × µm) formed from the apical part of the implant (lower) (Figure 2). Each measurement
was performed by one experienced examiner using specific image software (Image-Pro
Plus, Media Cybernetics, Silver Spring, MA, USA). 3D photographs of the samples were
reconstructed and the amount of fresh bone forming around implants was determined using
micro-computed tomography scanners (SkyScan 1076, Skyscan, Aartselarr, Belgium) inside
the area of interest (ROI) box at a resolution of 35 um (achieved using 100 kV and 100 uA).
ROI box was set with dimension of 1.30 mm (x axis) × 1.30 mm (y axis) × 0.45 mm (z axis)
(Figure 3).
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2.7. Histological and Histomorphometric A alysis (H&E, Russell-Movat Pentachrome: Bone
Volume, Bone-Implant Contact) and Immunohistochemistry (Human nuclei A, BrdU)
The specimens were dehydrated for 1 week at 2 h intervals using graded alcohols of 70%,
80%, 95% and 100%. The specimens were then placed in Technovit 7200 (Heraeus Kulzer,
Dormagen, Germany) and ethanol (1:3, 1:1, and 3:1 ratio) and sectioned using a diamond saw
into the buccolingual plane (Exakt 300, Kulzer, Norderstedt, Germany). The central segment was
reduced to a final thickness of approximately 15 µm from each implant site by micro grinding
and polished with a cutting-grinding system (Exakt 400CS, Exakt Apparatebau, Norderstedt,
Germany) and finally stained with hematoxylin and eosin (H&E) and pentachrome stain by
Russell–Movat (American Master Tech, Lodi, CA, USA). The stained specimens were captured
using a light microscope (Leica DM 2500, Leica Microsystems, Wetzlar, Germany) at ×12.5,
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×50 and ×100 magnification. The new bone volume (BV) and new bone-implant contact
(BIC) within the ROI box around the implants were measured by imaging analyses system
(Image-Pro Plus 4.5 Media Cybernetics Inc., Silver Spring, MD, USA). The ROI box was set
with dimensions of 1.30 mm (x axis) × 1.30 mm (y axis) (Figure 3).
Immunohistochemistry analysis was conducted according to a previously reported
study [19]. Briefly, paraffin samples were de-paraffinized and hydrated. Then, antigen
retrieval was carried out with sodium citrate buffer (10 mM Sodium citrate, pH 6.0, 0.05%
Tween 20). The endogenous hyperoxidase was blocked with 0.3% H2O2 in PBS. After
incubation of the sections in blocking buffer, using biotinylated anti-mouse or anti-rabbit
secondary antibodies, all the bound antibodies were found, followed by the addition of
complex avidin-peroxidase. Counter-staining was performed with hematoxylin. Antibody
dilutions used in this study were as follows: human nuclear A antigen 1:25 (ab191181,
Abcam, Cambridge, MA, USA).
2.8. Statistical Analysis
The results from the radiological, histomorphometrical and immunohistochemical
analysis were expressed as the means +SDs and difference between groups were analyzed
using SPSS (version 23.0, IBM Corporation, NY, USA). Statistical significance was ana-
lyzed by one-way ANOVA. Post-hoc Duncan’s multiple-range test was used to identify
statistically significant difference, with a significance level of 5%.
3. Results
3.1. Surface Analysis by SEM
The disparity in cell morphology and surface features was clearly seen from the
surface of the machined and SLA-treated titanium discs. SEM analysis showed that d-
hMSCs seemed to be adhered well across the whole surface from day 1 regardless of the
surface type and use of osteogenic induction media (Figure 4). From day 5 of culture,
the morphology of d-hMSCs under osteogenic condition and d-hMSCs cultured on SLA
surface could not be discerned as SEM images revealed the progressive deposition of the
matrix, characterized by the appearance of circular nodule formation and decrease in cell
number. By day 7 of cell culture, the basal surface of the titanium discs was covered by
the cell population and evidence of mineralized crystalline-like structure became more
evident. This appearance was clearly distinguishable from that of the cells cultured on the
machined surface without osteogenic induction media.
3.2. Expression of Osteogenic Genes of d-hMSCs (RT-PCR)
RT-PCR analysis measured the expression of osteogenic genes including RUNX2,
COL1, BGP and IBSP of d-hMSCs’ proliferation on differently surface-treated titanium
discs after 7 days and 28 days of initial cell culture. D-hMSCs cultured on traditional
cell plate were used as a control to normalize the results obtained in the RT-PCR analysis.
From the results of day 7, it was clearly noted that d-hMSCs cultured on SLA-treated discs
displayed greater bone-related gene expression than d-hMSCs cultured on conventional
cell plate and machined titanium discs, although there was no statistically significant
difference among the groups (p > 0.05). On the other hand, COL1, a representative early
osteogenic marker, was rather lesser evident on SLA-treated surfaces than machined
surfaces, suggesting progression of osteogenic differentiation. Although statistically not
important, 28 days after initial cell culture, IBSP and BGP expression of d-hMSC culture on
SLA-treated titanium discs was also observed to be greater than that on machined titanium
discs (p > 0.05) (Figure 5).
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3.3. Radiological Analysis
As aforementioned, new bone volume (µm2) was determined at two points from
plain X-ray images, (a) upper an (b) lower. At 2 weeks, the new bone volume (upper)
measured in the control gro -treated surface discs was rather greater than t t
of the d-hMSCs group, showin egative effect of d-hMSCs on new bone formation.
However, in the 12 week group, such a negative effect had been compensated for, showing
that the d-hMSCs group demonstrated greater new bone volume than the control group
regardless of the surface type (p > 0.05). On the other hand, the new bone volume measured
in the lower part of the implant (lower), the area in which the cells are most prone to be
active due to the orientation of injection, displayed greater new bone formation in d-hMSCs
group at both 2 weeks and 12 weeks. In particular, when comparing new bone volume
(lower) measured from the SLA-treated surface of the control group and the d-hMSCs
group, the d-hMSC group showed statistically significantly greater new b ne volume than
the control group (p < 0.05). Micro CT results w ich measured new bone volume within the
ROI region are in accordance with the results of the measurement from plain X-ray images.
Although statistically not significant, the d-hMSCs group at 12 weeks demonstrated a
greater new bone volume than the control group regardless of the surface type (Figure 6).
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engrafting still sho ed opening of the defect, although a very s all a ount of ne bone
for ation as observed near the defect margin. Additionally, the amount of adipose
tissue which was abundantly found in the 2-week group was dramatically reduced in
all groups and dense connective tissue was no longer identified (Figure 7). The results
of the histomorphometric analysis are summarized in Figure 8. The average BIC values
measured within the ROI for the control group (machined, SLA) were 375.25 (µm2) and
343.57(µm2) at 2 weeks, and 402.78 (µm2) and 486.34 (µm2) at 12 weeks, respectively. The
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average BIC values measured within the ROI for the d-hMSCs group (machined, SLA)
were 613.03 (µm2) and 597.03 (µm2) at 2 weeks, and 655.67 (µm2) and 855.69 (µm2) at
12 weeks, respectively. There was no statistically significant difference in BIC values at any
time point between the control group and the d-hMSCs group (p > 0.05).
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As can be expected from the results of histologic analysis, new bone volume (BV%)
measured within the ROI in the d-hMSCs group showed a significantly increased formation
compared to that of the control group. The average BV (%) values measured within the
ROI for the control group (machined, SLA) were 7.47% and 8.72% at 2 weeks, and 19.27%
and 17.36% at 12 weeks, respectively. The average BV (%) values measured within the ROI
for the d-hMSCs group (machined, SLA) were 36.90 (%) and 49.64 (%) at 2 weeks, and 34.39
(%) and 53.07 (%) at 12 weeks, respectively. At 2 weeks, regardless of surface type, the
d-hMSCs group showed statistically significantly increased new bone formation compared
to that of the control group (p < 0.05). Although the average BV (%) values did not differ
significantly between the control group and the d-hMSCs group with machined surface at
12 weeks, there was significant difference in BV (%) values between the control group and
the d-hMSCs group with SLA-treated surface.
When comparing the maturity of bone depending on the time point, Russell–Movat
pentachrome staining further confirmed that the d-hMSCs group at 12 weeks showed higher
histological maturity of bone than the d-hMSCs group at 2 weeks. As shown in Figure 9, new
bone network found in the d-hMSCs group at 2 weeks stained as green/yellow, indicative
of woven bone, while new bone bridge found in the d-hMSCs group at 12 weeks stained as
red, indicative of lamellar bone, and this color is similar to that of the intact bony tissue
next to the defect (Figure 9).
3.5. Immunohistochemistry
The immunohistochemical analysis revealed that human nuclei A exhibited to moder-
ate to strong expression in the d-hMSCs group at 2 weeks and the expression was mostly
confined to the area below the implant, in which the d-hMSCs were most likely deposited.
Partial expression was also identified alongside the body of implant. However, the level
of expression was not as strong as that found in the bottom of the implant. At 12 weeks,
human nuclei A still exhibited weak to moderate expression in the d-hMSCs group, show-
ing the survival of the d-hMSCs injected, but the level of expression was weaker than that
found at 2 weeks (Figure 10).
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weeks post-surgery (Russell–Movat pentachrome stain; original magnification ×50, ×100). 
Figure 9. Light-microscopy views of the control group (without d-hMSCs) and the d-hMSCs group sacrificed at 2 and
12 weeks post-surgery (Russell–Movat pentachrome stain; original magnification ×50, ×100).
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4. Discussion
Many contemporary studies have demonstrated th rapeuti benefits of engrafted
hMSCs for local bone regeneration without any significant side effects [20–23]. However,
several studies have also reported that most engrafted hMSCs were not found in the target
area and mostly died or were entrapped in the lung if intravenously injected, limiting
the use of hMSCs as a routine clinical application [24]. Indeed, more preclinical research
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is required to accurately assess the therapeutic potential of hMSCs by mimicking site-
specific clinical conditions. In this study, we attempted to investigate the behavior of
d-hMSCs, which have more advantages than hMSCs obtained from bone marrow of the
iliac crest, [25,26] in response to differently surface-treated implants, and also the effect of
d-hMSCs on local osteogenesis around an implant depending on the different surface type,
evaluated using a tibia model in rabbits.
The results from SEM analysis clearly showed that a more active d-hMSCs cellular
response was identified on SLA-treated surfaces than machined surfaces and this dif-
ference became more discernible from day 5 of initial culture, showing circular nodule
formation in a dispersed form. From day 7, mineralized crystalline-like structure was
identifiable on SLA-treated surfaces and on machined surfaces with osteogenic induction
media, while this feature could not be found with the cells cultured on machined surfaces
without osteogenic induction media. These time-dependent, surface-dependent cellular
morphological changes were confirmed quantitatively throughout the results of RT-PCR,
showing greater bone-related gene expression including COL-1, RUX2, IBSP and BGP on
SLA-treated surfaces although no statistically significant difference in the level of expres-
sion was identified between SLA-treated surfaces and machined surfaces (p > 0.05). These
results were in accordance with those of our previous study, which reported the increased
early osteogenic markers (COL1, RUNX2) with dental stem cell-derived induced pluripo-
tent stem cells cultured on the SLA-treated titanium discs in comparison to machined
titanium discs [27]. As reported in many previous studies [28–30], it has been generally
accepted that the rougher the implant surface, the more active the hMSC cell response
present in terms of adhesion to the surface and differentiation into osteoblast through
activation of RhoA/ROCK pathway, which ultimately influences the transcription factor
RUNX2 to control osteoblast differentiation and matrix mineralization [31,32]. Therefore,
it was once more confirmed throughout this study that the cell response of d-hMSCs can
be affected by the topography of implant materials and it may be further anticipated that
manipulating topography of implant surfaces could control the fate of d-hMSCs for bone
tissue engineering applications.
In addition to the in vitro analysis of d-hMSCs, in vivo cell transplantation studies
were also performed, since the ultimate purpose of the present study was to evaluate
if the d-hMSCs can survive on the defects and directly regenerate bone around an im-
plant. Although calvarial defect models is a most frequently used defect model to assess
in vivo osteogenesis, this model only evaluates intramembranous bone formation in a
non-load bearing area [33]. Instead, we used a tibia defect model in the present study to
accurately access the bone-forming ability around implants placed in load-bearing bone,
which better mimics an actual clinical situation. Additionally, since it is well known that
the choice of an appropriate scaffold, which should enable cell delivery, survival and
attachment, is a pivotal factor in determining the success of cell transplantation, we used
cytocompatible MatrigelTM, which does not directly contribute to bone formation, so that
the pure osteogenic effect of cell transplantation could be deduced from the results of the
d-hMSCs group.
According to the results of radiographic and histomophometric analysis, the os-
teogenic effect d-hMSCs around an implant was clearly identified, showing the greater
new bone formation especially in the early phase of bone regeneration. In addition to
direct conversion of hMSCs into osteoblast, Totelli et al. suggested ”indirect” action of
hMSCs, insisting engrafted hMSCs may act as a “signaling center”, orchestrating the host
response to the injury, especially in attracting host vasculature [34]. Sharing the same point
of view, Le Blanc K et al. reported that such a ”trophic” or ”paracrine” effect of hMSCs can
be critical in initial inflammatory phases as hMSCs are known to have anti-inflammatory
functions [35,36]. In this sense, the significant increase in bone formation in the d-hMSCs
group at 2 weeks can be interpreted in addition to their direct role as a source of new
osteoblasts. These results are supported by the results of histomorphometric analysis, in
which significant difference in new bone volume (%) was identified solely in the SLA-
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treated surface group at 12 week whereas a significantly increased osteogenic effect in
the d-hMSC group was identified regardless of surface type. Again, it can be interpreted
that the effect of d-hMSCs had been maximized in the early phase of bone regeneration,
followed by additional osteogenesis effect of the SLA-treated surface at a later phase of
bone regeneration.
Although it was not very hard to differentiate between newly formed bone quality of
the d-hMSCs group at 2 weeks and that of the d-hMSCs group at 12 weeks from histologic
images, the absolute value of new bone volume (%) did not show any difference. This
may be due to spontaneous bone healing tendencies of a rabbit model as a result of
endosteum and periosteal reaction. A. Piattelli et al. [37] reported that in 2 to 6 months,
the newly formed bone around the implant was almost the same as the existing bone. In
the present study, therefore, the results of the 12 week group might have been hindered by
this limitation. To compare the maturity of bone, Russell–Movat pentachrome staining was
employed depending on the time point, and verified that the d-hMSCs group at 12 weeks
showed higher histological maturity of bone than the d-hMSCs group at 2 weeks.
Lastly, but very importantly, we assessed the survival time of engrafted d-hMSCs, since
it was reported that most d-hMSCs are deemed to be dead or not function in target areas,
which may result from various reasons including inappropriate cell density [38], regulation
of microenvironment [39] and high oxygen tension [40]. The immunohistochemical analysis
revealed that human nuclei A still exhibited moderate expression in the d-hMSCs group,
showing the survival of the d-hMSCs up to 12 weeks post-engraftment, although the level
of expression was weaker than that found at 2 weeks, which suggests the attenuating of
the function of d-hMSCs at 12 weeks.
In summary, all parameters investigated in this study, including in vitro analysis,
radiographic, histologic, histomorphometric and immunohistochemical analysis, were
consistent with each other and revealed promising results that d-hMSCs enhance the new
bone formation around an implant with the reinforced increase in osteogenic potential of
SLA-treated surfaces. Nevertheless, it has to be admitted that translations of these results
into clinical practice may encounter many challenges beyond safety concerns described
previously [41]. Further study may be required in attempts to improve the longevity of
the d-hMSCs and to determine the optimal conditions in which the osteogenic potency of
d-hMSCs can be maximized.
5. Conclusions
Within the limitations of the present study, transplantation of d-hMSCs along with
use of appropriate implant surface type can be used as promising tools to reconstruct an
appropriate regenerative microenvironment, thereby increasing bone regeneration capacity.
This method may further provide a possible strategy for significantly reducing time of
current treatment modalities incorporated with dental implants.
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